Continuing Diversification of
            <i>Neisseria meningitidis</i>
            W135 as a Primary Cause of Meningococcal Disease after Emergence of the Serogroup in 2000

Taha, Muhamed‐Kheir; Giorgini, Dario; Ducos-Galand, Magaly; Alonso, Jean-Michel

doi:10.1128/jcm.42.9.4158-4163.2004

Cited by 66 publications

(49 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VOL. 19, 2006 VACCINE PREVENTION OF MENINGOCOCCAL INFECTION 147 However, this serogroup caused a worldwide outbreak that started during the 2000 annual Hajj pilgrimage to Mecca (229,275,335,336). The outbreak was caused by a serogroup W-135 clone that was genetically related to a virulent serogroup C clone.…”

Section: Capsular Switching and Other Antigenic Variationmentioning

confidence: 99%

See 1 more Smart Citation

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

SUMMARY Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.

show abstract

Section: Capsular Switching and Other Antigenic Variationmentioning

confidence: 99%

“…In 2000, a W-135 outbreak occurred in Saudi Arabia during the annual Hajj pilgrimage (79,229,275,(335)(336)(337). The outbreak strain spread to multiple other countries and caused a large epidemic in Burkina Faso in 2002.…”

Section: Meningococcal Serogroupsmentioning

confidence: 99%

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

show abstract

“…It is likely that the outbreak in 2000 and the global increase in menW disease were due to expansion of the ET-37 clone that has been in circulation since at least 1970 (24). New genetic lineages of menW that are independent of the Hajj-related strain have been reported (30).…”

mentioning

confidence: 99%

Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age

et al. 2005

View full text Add to dashboard Cite

An immunization campaign with meningococcal ACYW135 polysaccharide vaccine was conducted in 2003 by the Saudi Arabian Ministry of Health and included a study to evaluate the immune responses in children under 5 years of age in the Al Qassim region of Saudi Arabia. Children who were >24 months old were given one dose of tetravalent polysaccharide vaccine, while younger children were given two doses with an interval of 2 to 3 months. Blood samples were collected prevaccination and 1 month after the second dose for children younger than 24 months old and 1 month after the single dose for older children. Serogroup-specific antibody responses were determined by serum bactericidal antibody (SBA) assays and a tetraplex immunoglobulin G (IgG) bead assay. Significant increases in the proportions of individuals who were >24 months old with SBA titers of >8 were observed pre-to postvaccination for all serogroups. Age-dependent increases in the percentage of individuals with SBA titers of >8 1 month postvaccination were observed for each serogroup. Age-dependent increases in postvaccination IgG levels were observed for serogroup A (menA), serogroup W135 (menW), and serogroup Y (menY) but not for serogroup C (menC). Two doses of tetravalent polysaccharide vaccine in individuals who were <18 months old were poorly immunogenic for menC, menW, and menY. However, for menA, 42% of the children who were 18 months old were putatively protected with SBA titers of >8. A high percentage of subjects who were >2 years of age were putatively protected for menA; a similar level was observed for menY for children who were 4 years of age but not for younger children. However, for menC and menW poor levels of putative protection were still evident at 4 years of age.

show abstract

“…In the last 7 years worldwide, a marked increase in the number of group W135 isolates has occurred, particularly those with the strain type W:2a:P1.5,2 from the sequence type 11 (ST-11) clonal complex. Approximately 10% of cases in Europe and North America are now due to meningococci with the W135 capsular type (23,25,26), and there have been two large outbreaks of disease. The first, occurring at the Hajj, Saudi Arabia, in 2000, resulted in the considerable global spread of the ST-11 strain W:2a:P1.5,2 as pilgrims returned to their home countries (28).…”

mentioning

confidence: 99%

Evidence for Capsule Switching between Carried and Disease-CausingNeisseria meningitidisStrains

Beddek

Kroll

et al. 2009

Infect Immun

View full text Add to dashboard Cite

Changing antigenic structure such as with capsule polysaccharide is a common strategy for bacterial pathogens to evade a host immune system. The recent emergence of an invasive W:2a:P1.7-2,4 sequence type 11 (ST-11) strain of Neisseria meningitidis in New Zealand, an uncommon serogroup/serotype in New Zealand disease cases, was investigated for its genetic origins. Molecular typing of 107 meningococcal isolates with similar serotyping characteristics was undertaken to determine genetic relationships. Results indicated that the W:2a:P1.7-2,4 strain had emerged via capsule switching from a group C strain (C:2a:P1.7-2,4). Neither the upstream nor downstream sites of recombination could be elucidated, but sequence analysis demonstrated that at least 45 kb of DNA was involved in the recombination, including the entire capsule gene cluster. The oatWY gene carried by the W:2a:P1.7-2,4 strain contained the insertion sequence element IS1301, one of five variants of oatWY found in group W135 strains belonging to the carriage-associated ST-22 clonal complex. This suggested that the origin of the capsule genes carried by the invasive W:2a:P1.7-2,4 strain is carriage associated. These results provide novel evidence for the long-standing dogma that disease-associated strains acquire antigenic structure from carriage-associated strains. Moreover, the capsule switch described here has arisen from the exchange of the entire capsule locus.

show abstract

Continuing Diversification of Neisseria meningitidis W135 as a Primary Cause of Meningococcal Disease after Emergence of the Serogroup in 2000

Cited by 66 publications

References 19 publications

Prospects for Vaccine Prevention of Meningococcal Infection

Prospects for Vaccine Prevention of Meningococcal Infection

Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age

Evidence for Capsule Switching between Carried and Disease-CausingNeisseria meningitidisStrains

Contact Info

Product

Resources

About